Perrigo Suffers As It Waves Goodbye To Rx
CEO Kessler Acknowledges ‘Disappointing’ Q3 As Prescription Business Divested
Perrigo CEO Murray Kessler has acknowledged “disappointing” third quarter results for the company during a transitional quarter that saw it finally divest its Rx prescription generics business ahead of its upcoming acquisition of consumer healthcare specialist HRA Pharma.
